News
VIVE
--
0.00%
--
Viveve Announces Issuance Of New Device And Methods Patent In US
Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No.
Benzinga · 6d ago
Viveve Announces Issuance of New Device and Methods Patent in U.S.
ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 10,...
ACCESSWIRE · 6d ago
Viveve Announces Adjournment of Annual Meeting
* Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time * Company encourages stockholders to cast their votesENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's int...
ACCESSWIRE · 06/02 20:05
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 05/14 11:59
BRIEF-Viveve Medical Posts Quarterly Loss Per Share Of $0.80
reuters.com · 05/13 22:53
Recap: Viveve Medical Q1 Earnings
Shares of Viveve Medical (NASDAQ:VIVE) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 2.44% year over year to ($0.80), which missed the estimate of ($0.51).
Benzinga · 05/13 21:15
Viveve Medical EPS misses by $0.29, beats on revenue
Viveve Medical (VIVE): Q1 GAAP EPS of -$0.80 misses by $0.29.Revenue of $1.45M (+11.5% Y/Y) beats by $0.12M.Shares +0.8%.Press Release
Seekingalpha · 05/13 20:36
Viveve Medical Q1 EPS $(0.80) Misses $(0.51) Estimate, Sales $1.50M Beat $1.33M Estimate
Viveve Medical (NASDAQ:VIVE) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.51) by 56.86 percent. This is a 2.44 percent increase over losses of $(0.82) per share from
Benzinga · 05/13 20:17
Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update
ACCESSWIRE · 05/13 20:02
-- Earnings Flash (VIVE) VIVEVE MEDICAL Reports Q1 Revenue $1.5M, vs. Street Est of $1.33M
MT Newswires · 05/13 16:06
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 05/13 08:15
Viveve Announces Adjournment Of Annual Meeting
 Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due to a lack of quorum. The
Benzinga · 05/11 16:33
Viveve To Host Conference Call on May 13, 2021 To Report First Quarter Financial Results and Provide Corporate Update
May 06, 2021 (ACCESSWIRE via COMTEX) -- ENGLEWOOD, CO / ACCESSWIRE / May 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused...
ACCESSWIRE · 05/06 12:28
Viveve Medical Stock Shows Every Sign Of Being Modestly Overvalued
GuruFocus News · 04/29 15:12
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan
ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No.
ACCESSWIRE · 04/01 13:28
Viveve Announces Expansion Of IP Portfolio With Patent Issuance In Taiwan
Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for
Benzinga · 04/01 12:29
BRIEF-Viveve Medical Files Prospectus Related To Resale Of Up To 3.5 Million Shares By Lincoln Park Capital Fund
reuters.com · 03/31 21:17
BRIEF-Viveve Medical Inc Says On March 31 Co, Lincoln Park Capital Fund Entered Into First Amendment To Purchase Agreement
reuters.com · 03/31 21:14
Webull provides a variety of real-time VIVE stock news. You can receive the latest news about Viveve Medical through multiple platforms. This information may help you make smarter investment decisions.
About VIVE
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.